Vical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference

SAN DIEGO, June 13, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq: VICL) announced today that the company will present clinical data on its completed HSV-2 Phase 1/2 trial at the American Society of Microbiology (ASM) Microbe/ICAAC 2016 conference (Boston, June 16 - 20).  

Dr. Mammen P. “Anza” Mammen, M.D. Vical’s Vice President, Clinical Vaccines, will present in the conference’s clinical virology session on June 20, 2016 at approximately 10:30 am. Trial results, including safety and efficacy endpoints, will be presented in the oral late-breaker presentation. The slides presented by Dr. Mammen will be available on Vical’s website after the presentation.

About VicalVical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.

Contact: 
Andrew Hopkins
(858) 646-1127
Website:  www.vical.com

You May Also Be Interested In

• InterContinental Hotels Group PLC Announces Transaction in Own Shares - Apr 19
• QPR Software Plc Interim report January–March 2024
• Middlefield Canadian Income PCC - Annual Financial Report